Thursday, October 16, 2014 1:18:52 AM
https://opkodd.files.wordpress.com/2014/10/asco_university_logo.jpg&h=55
Improving the specificity of prostate cancer screening for early detection of lethal disease. ( http://meetinglibrary.asco.org/content/133629-144?utm_content=8913138&utm_medium=social&utm_source=twitter )
Meeting:
2014 ASCO Annual Meeting
Category:
Genitourinary (Prostate) Cancer
Subcategory:
Prostate Cancer
Session Type and Session Title:
General Poster Session, Genitourinary (Prostate) Cancer
Abstract Number:
5081
Citation:
J Clin Oncol 32:5s, 2014 (suppl; abstr 5081)
Author(s):
Hans Lilja, Andrew J. Vickers, Daniel Sjoberg, Robert Johansson, Torvald Granfors, Mattias Johansson, Kim Pettersson, Peter T. Scardino, Göran Hallmans, Pär Stattin; Memorial Sloan-Kettering Cancer Center, New York, NY; Umeå University, Umeå, Sweden; Central Hospital, Västerås, Sweden; The International Agency for Research, Lyon, France; University of Turku, Turku, Finland
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).
Abstract Disclosures ( http://apps.asco.org/coidisplay/generateAbstractCOI.aspx?abstractId=133629 )
Abstract:
Background: PSA is used to detect prostate cancer, but many men need to be screened, biopsied, and diagnosed to prevent one cancer death. We sought to increase the specificity of screening for lethal prostate cancer. Methods: We conducted a nested case-control study to determine the relationship between four kallikrein markers (kallikrein related peptidase 2, total, free, and intact PSA) and long-term risk of metastasis. Of the 40,379 men providing blood at age 40, 50, and 60 during 1986-2009 for the Västerbotten Intervention Project, 12,561 were followed for over 15 years. Using the Swedish Cancer Registry, 1,423 incident prostate cancer cases and 235 men with evidence of distant metastases were identified. Kallikrein markers were measured in cryopreserved blood from cases and controls. Results: Risk of prostate cancer metastasis at 20 years was higher (16-fold at age 60, 7-fold at age 50, 3-fold at age 40) among men with PSA in top quartile than men with PSA below median. Most metastatic cases occurred in men with PSA in top quartile at age 50 (69%) or 60 (73%). Among men with PSA levels above median, a pre-specified model based on four kallikrein markers improved prediction of distant metastasis documented 10-20 years later compared to PSA alone. Among men with PSA =2 ng/ml at age 50, discrimination increased from 0.77 (PSA alone) to 0.88 (kallikrein panel); for men with PSA =2 ng/ml at age 60, discrimination increased from 0.81 to 0.87. We also conducted a decision analysis evaluating hypothetical outcomes had the panel been used to aid decisions about biopsy in this cohort. Using the biopsy cutoff used in the European randomized prostate cancer screening trial (PSA =3 ng/ml) would have resulted in biopsies performed on 15.5% of men with blood drawn at age 60. This rate would have been reduced by 38% if biopsy were restricted to those with =7.5% risk of high-grade cancer according to the panel. However, 10 to 15-year risk of distant metastases was only 0.18% to 1.16% in this group; a 15-year risk of metastases less than an eighth of that for those with PSA =3 ng/ml and =7.5% risk score. Conclusions: The specificity of PSA screening can be improved by focusing on men with modestly elevated PSA at age 50-60 and by reflex testing of four kallikrein markers.
Recent OPK News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/20/2024 06:56:10 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 09/18/2024 08:13:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 09:00:42 PM
- Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health • PR Newswire (US) • 09/16/2024 11:30:00 AM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 08/30/2024 09:01:33 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/23/2024 09:33:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 09:23:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:50:25 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/12/2024 10:27:05 PM
- Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 08/09/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 09:39:52 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:12:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:07:42 PM
- OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results • GlobeNewswire Inc. • 08/07/2024 08:06:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 08:21:51 PM
- OPKO Health to Report Second Quarter 2024 Financial Results on August 7, 2024 • GlobeNewswire Inc. • 08/01/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/31/2024 09:03:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:49:22 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 07/26/2024 11:43:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:18:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:15:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:11:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:08:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 11:05:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/23/2024 09:16:09 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM